Loss of Tissue Expression of Interleukin-10 Promotes the Disease Progression of Colorectal Carcinoma

Overview

Journal Surg Today

Specialty General Surgery

Date 2009 Dec 29

PMID 20037839

Citations 13

Authors

Yuji Toiyama

Chikao Miki

Yasuhiro Inoue

Sayaka Minobe

Hiroko Urano

Masato Kusunoki

Affiliations

Soon will be listed here.

Abstract

Purpose: Interleukin-10 (IL-10) is a unique cytokine that is thought to be a potent immunostimulatory and immunosuppressive factor. The aim of this study was to investigate IL-10 expression in colorectal cancer, and clarify its relationship to the clinicopathological findings and prognosis.

Methods: Tissue samples were collected from 92 patients with colorectal cancer and adjacent normal mucosa. The expression of IL-10 in colorectal cancer tissues was evaluated by immunohistochemistry. Tissue levels of IL-10 were measured by enzyme-linked immunosorbent assay.

Results: The mean concentration of IL-10 did not significantly differ between the cancer tissue and adjacent normal mucosa. The IL-10 concentration in cancer tissue with positive staining immunohistochemically was significantly higher than that without IL-10 staining. The IL-10 level in cancer tissue decreased in accordance with advanced-stage serosal invasion and lymph node involvement, and thus predicted poor survival in patients undergoing surgery with curative intent. A Cox multivariate analysis demonstrated that a decreased IL-10 level in cancer tissue was an independent risk factor for poor survival.

Conclusion: The tumor IL-10 level in colorectal cancer was inversely correlated with serosal invasion and lymph node metastasis, which thus reflected tumor progression. Evaluating the tumor expression of IL-10 may therefore provide valuable information for predicting the long-term survival in patients undergoing surgery with curative intent.

Citing Articles

The complex role of IL-10 in malignant ascites: a review.

Huang Y, Zou K, Jiang H, Li Z Cancer Immunol Immunother. 2024; 73(2):32.

PMID: 38279997 PMC: 10821842. DOI: 10.1007/s00262-023-03616-y.

Roles of benefit finding in psychological and inflammatory adjustments in persons with colorectal cancer: a prospective analysis on the multidimensionality of benefit finding.

Tsai T, Lee G, Ting A, Antoni M, Mendez A, Carver C Psychol Health. 2023; 40(3):492-510.

PMID: 37488833 PMC: 10805970. DOI: 10.1080/08870446.2023.2238280.

Selective Role of TNFα and IL10 in Regulation of Barrier Properties of the Colon in DMH-Induced Tumor and Healthy Rats.

Bekusova V, Zudova T, Fatyykhov I, Fedorova A, Amasheh S, Markov A Int J Mol Sci. 2022; 23(24).

PMID: 36555251 PMC: 9779473. DOI: 10.3390/ijms232415610.

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.

Jimbu L, Mesaros O, Neaga A, Nanut A, Tomuleasa C, Dima D Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832887 PMC: 8620891. DOI: 10.3390/ph14111105.

Interleukin-10: A double-edged sword in breast cancer.

Chang C, Lam H, Hsu H, Jiang S Tzu Chi Med J. 2021; 33(3):203-211.

PMID: 34386356 PMC: 8323643. DOI: 10.4103/tcmj.tcmj_162_20.

References

Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A . Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol. 1995; 155(6):3112-23. View

Cortes J, Talpaz M, Cabanillas F, Seymour J, Kurzrock R . Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995; 85(9):2516-20. View

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

de Waal Malefyt R, Haanen J, Spits H, Roncarolo M, Te Velde A, Figdor C . Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991; 174(4):915-24. PMC: 2118975. DOI: 10.1084/jem.174.4.915. View

Gastl G, Abrams J, Nanus D, Oosterkamp R, Silver J, Liu F . Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer. 1993; 55(1):96-101. DOI: 10.1002/ijc.2910550118. View

Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J . T cells and aging, January 2002 update. Front Biosci. 2002; 7:d1056-183. DOI: 10.2741/a831. View

Giacomelli L, Gianni W, Belfiore C, Gandini O, Repetto L, Filippini A . Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clin Cancer Res. 2003; 9(7):2678-82. View

Kim J, Modlin R, Moy R, Dubinett S, McHugh T, Nickoloff B . IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 1995; 155(4):2240-7. View

Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson J . Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood. 2000; 96(7):2568-73. View

10.

Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y . Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004; 64(5):1843-52. DOI: 10.1158/0008-5472.can-03-3179. View

11.

Berman R, Suzuki T, Tahara H, Robbins P, Narula S, Lotze M . Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996; 157(1):231-8. View

12.

Miki C, Tanaka K, Inoue Y, Araki T, Ohi M, Mohri Y . Perioperative host-tumor inflammatory interactions: a potential trigger for disease recurrence following a curative resection for colorectal cancer. Surg Today. 2008; 38(7):579-84. DOI: 10.1007/s00595-007-3674-6. View

13.

Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D . Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19(3):239-47. DOI: 10.1081/cnv-100102550. View

14.

Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P . Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res. 2002; 22(4):473-82. DOI: 10.1089/10799900252952262. View

15.

Gerard C, Bruyns C, Delvaux A, Baudson N, Dargent J, Goldman M . Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther. 1996; 7(1):23-31. DOI: 10.1089/hum.1996.7.1-23. View

16.

Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H . Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000; 79(3):110-3. DOI: 10.1007/s002770050564. View

17.

Dummer W, Becker J, Schwaaf A, Leverkus M, Moll T, Brocker E . Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995; 5(1):67-8. DOI: 10.1097/00008390-199502000-00008. View

18.

Lu C, Soria J, Tang X, Xu X, Wang L, Mao L . Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol. 2004; 22(22):4575-83. DOI: 10.1200/JCO.2004.01.091. View

19.

Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H . IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol. 1992; 148(3):808-14. View

20.

Grunfeld C . Leptin and the immunosuppression of malnutrition. J Clin Endocrinol Metab. 2002; 87(7):3038-9. DOI: 10.1210/jcem.87.7.8778. View